Mimetica is a private Australian company focused on the development of products for the treatment of acne.
Mimetica was founded in 2001 to develop a drug discovery platform technology based on the rational design of small molecules that mimic natural peptide hormones. Mimetica has successfully applied this technology to generate novel drug candidates that target the melancortin-5 receptor (MC5R). One of these, MTC896, has advanced into Phase 2 clinical development as a potential new topical treatment for acne.
Our objective is to conduct further clinical development of MTC896 to demonstrate clinical effectiveness in humans with acne. If the trials are successful MTC896 is expected to be the first topically administered product of this type and will offer a new approach to the way acne is treated.